Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Riluzole treatment and a diet containing high glycemic index foods interact 'synergistically' to slow ALS progression, ...

Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

Italian authorities released the director of a notorious detention camp who had been arrested in Turin on an ICC war crimes warrant. Italian police were acting on an arrest warrant from the ...

Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The collaboration agreement centres around Alchemab’s antibody discovery platform, ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

The Big Pharma has inked a deal with British biotech Alchemab Therapeutics to develop new antibodies for ALS. Under the terms of the deal, Alchemab and Lilly will work together on up to five new ...

The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, and commercialize up to five novel therapeutics for the treatment of ...

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. Alchemab has acquired hundreds of ALS samples ...

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire ...